31 /100
MEDIUM RISK
Score updated May 30, 2026

NSRX — Nasus Pharma Ltd. Dilution Risk Tracker

Track NSRX dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track NSRX — Get alerts when the score changes →

📊 Score Breakdown

📋 Offering Ability
20
💰 Cash Runway
40
📊 Float Risk
45
⚠️ Warrant Exposure
15
🔄Convertible Debt

🌦️ Dilution Forecast

☀️
Clear
No significant dilution signals
7%
📉 Score Deterioration 15%
• Score climbed 7 points (worsening)
🔔 Track NSRX — Get forecast alerts →

💹 Market Data

Market Cap$39.35M
Shares Outstanding11.71M
Float4.86M
Cash$4.29M
Debt$118.0K
Short InterestN/A

🏛 Institutional Holdings

2 institutional holders · 2.4K shares
#1 Morgan Stanley 2.0K shares
#2 UBS Group AG 378 shares

📉 Short Interest

Short Interest155.0K
Days to Cover2.1
% of Float3.4%
FINRA data as of May 15, 2026

📁 Recent SEC Activity

xbrl XBRL CONVERTIBLE Dec 31, 2025
13F-HR BENEFICIAL OWNERSHIP Dec 31, 2025
13F-HR BENEFICIAL OWNERSHIP Dec 31, 2025
Full SEC filing analysis available with free account

📰 Recent News

No recent news
Track NSRX Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking NSRX — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required
🔬 More Research for NSRX
📊 NSRX FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 NSRX Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.